EW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edwards Lifesciences looks like a good buy right now for a beginner with a long-term mindset and $50,000-$100,000 to invest. The stock has a constructive technical setup, strong Q1 growth, and broadly favorable analyst sentiment after a beat-and-raise quarter. With the current pre-market price at 82.76 and no major negative event pressure, I would be comfortable buying it now rather than waiting for a better entry.
EW is in a short-term bullish structure: SMA_5 > SMA_20 > SMA_200, which supports an uptrend. MACD histogram is positive at 0.231, though slightly contracting, suggesting momentum is still positive but not accelerating sharply. RSI_6 at 52.0 is neutral, so the stock is not overbought. Price at 82.76 is very close to pivot 82.928, with immediate resistance at 84.611 and support at 81.245. Overall, the trend is positive and the current level is acceptable for entry.
["Q1 revenue grew 16.7% YoY, showing strong top-line momentum.", "EPS rose 8.2% YoY and net income increased 6.34% YoY.", "Analysts broadly raised targets after beat-and-raise results.", "Barclays raised target to $110 and kept Overweight.", "BTIG cited better-than-expected Q1 results and confident outlook.", "Wolfe upgraded the stock to Outperform on improving TAVR share opportunity.", "Management raised full-year revenue guidance and reiterated long-term growth targets.", "Recent news around CFO appointment is neutral-to-slightly positive for execution."]
["Gross margin declined slightly YoY to 78.01%.", "Some analysts still have Hold/Neutral ratings and view valuation as stretched.", "Options open interest leans bearish with put-call ratio above 1.0.", "Historical pattern data suggests some near-term downside probability over the next day/week.", "No strong insider or hedge fund accumulation trend is present.", "Congress trading is balanced, with one buy and one sell, so no strong political signal."]
In Q1 2026, Edwards Lifesciences delivered strong growth: revenue increased to $1.649B, up 16.7% YoY, net income rose 6.34% YoY to $380.7M, and EPS increased 8.2% YoY to $0.66. The only mild weakness was gross margin, which dipped slightly to 78.01%. For a long-term investor, this is a healthy earnings profile with good growth trends, especially for the latest quarter.
Analyst sentiment has improved recently after the Q1 beat and guidance raise. Barclays, BTIG, Evercore, BofA, Mizuho, and Wolfe are broadly positive, with price targets clustering around the low-to-mid $90s and Barclays reaching $110. However, there are still Hold/Neutral views from Truist, Baird, and Canaccord, indicating the Wall Street pros see upside but are somewhat split on valuation. Overall, the analyst trend is positive, with more upgrades/target raises than downgrades.
